Latest & greatest articles for constipation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on constipation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on constipation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for constipation

101. Toilet and defecation-specific behaviour of children with constipation, retentive faecal incontinence, non-retentive faecal incontinence and stool toileting refusal: a systematic review

Toilet and defecation-specific behaviour of children with constipation, retentive faecal incontinence, non-retentive faecal incontinence and stool toileting refusal: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2016 PROSPERO

102. Palliative care - constipation

Palliative care - constipation Palliative care - constipation - NICE CKS Share Palliative care - constipation: Summary Constipation is defecation that is unsatisfactory because of infrequent stools, difficult stool passage, or seemingly incomplete defecation. Stools are often dry and hard, and may be abnormally large or abnormally small. About 80% of people with cancer will require treatment with laxatives at some time. People receiving palliative care have multiple causes of constipation (...) , such as: Drugs, for example, opioid analgesics, antimuscarinic drugs, antacids. Secondary effects of disease, for example, dehydration, inadequate dietary fibre, inactivity, delirium, spinal cord compression, lack of privacy. Direct effects of malignant tumours, causing bowel obstruction, hypercalcaemia, nerve damage. When assessing a person with constipation in palliative care: The history should include information about the frequency and character of stools, discomfort, blood or mucus with the stool

2016 NICE Clinical Knowledge Summaries

103. Evaluation and Management of Constipation

Evaluation and Management of Constipation Copyright © The American Society of Colon & Rectal Surgeons, Inc. Unauthorized reproduction of this article is prohibited. 479 Diseases of the Colon & ReCtum Volume 59: 6 (2016) t he a merican s ociety of Colon and Rectal surgeons is dedicated to assuring high-quality patient care by advancing the science, prevention, and manage- ment of disorders and diseases of the colon, rectum, and anus. t he Clinical Practice Guidelines Committee is com- posed (...) specific procedure must be made by the physician in light of all of the cir- cumstances presented by the individual patient. STATEMENT OF THE PROBLEM Constipation is a benign condition that can have a signifi- cant impact on quality of life. t he prevalence has been es- timated to be as high as 30% in select populations and has been noted to be higher in women, nonwhites, those aged >65 years, and those with lower socioeconomic status. 1–6 Constipation is characterized by dysfunction of colonic

2016 American Society of Colon and Rectal Surgeons

104. The association between constipation and quality of life, health related quality of life and health status in adults: a systematic review protocol. Full Text available with Trip Pro

The association between constipation and quality of life, health related quality of life and health status in adults: a systematic review protocol. 26455744 2016 05 12 2018 12 02 2202-4433 13 6 2015 Jul 17 JBI database of systematic reviews and implementation reports JBI Database System Rev Implement Rep The association between constipation and quality of life, health related quality of life and health status in adults: a systematic review protocol. 45-55 10.11124/jbisrir-2015-1760 Trads Mette (...) M Danish Centre of Systematic Reviews: A Collaborating Centre of the Joanna Briggs Institute.. Pedersen Preben U PU Danish Centre of Systematic Reviews: A Collaborating Centre of the Joanna Briggs Institute.. eng Journal Article 2015 07 17 Australia JBI Database System Rev Implement Rep 101648258 2202-4433 IM Adult Constipation complications Female Health Status Humans Male Middle Aged Quality of Life Systematic Reviews as Topic constipation quality of life 2014 06 16 2015 03 16 2015 03 10 2015

2015 JBI database of systematic reviews and implementation reports

105. Interventions for preventing postpartum constipation. Full Text available with Trip Pro

Interventions for preventing postpartum constipation. Postpartum constipation, with symptoms such as pain or discomfort, straining, and hard stool, is a common condition affecting mothers. Haemorrhoids, pain at the episiotomy site, effects of pregnancy hormones and haematinics used in pregnancy can increase the risk of postpartum constipation. Eating a high-fibre diet and increasing fluid intake is usually encouraged, although laxatives are commonly used in relieving constipation (...) . The effectiveness and safety of available interventions for preventing postpartum constipation needs to be ascertained.To evaluate the effectiveness and safety of interventions for preventing postpartum constipation.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 April 2015), Stellenbosch University database, ProQuest Dissertation and Theses database, World Health Organization International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov (30 April 2015) and reference

2015 Cochrane

106. Interventions for treating constipation in pregnancy. (Abstract)

Interventions for treating constipation in pregnancy. Constipation is a common symptom experienced during pregnancy. It has a range of consequences from reduced quality of life and perception of physical health to haemorrhoids. An understanding of the effectiveness and safety of treatments for constipation in pregnancy is important for the clinician managing pregnant women.To assess the effectiveness and safety of interventions (pharmacological and non-pharmacological) for treating constipation (...) in pregnancy.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 April 2015), ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) (30 April 2015) and reference lists of retrieved studies.We considered all published, unpublished and ongoing randomised controlled trials (RCTs), cluster-RCTs and quasi-RCTs, evaluating interventions (pharmacological and non-pharmacological) for constipation in pregnancy. Cross-over studies were not eligible

2015 Cochrane

107. Linaclotide (Constella) in the symptomatic management of irritable bowel syndrome with constipation, The indication was granted...so what?

Linaclotide (Constella) in the symptomatic management of irritable bowel syndrome with constipation, The indication was granted...so what? 2015. DAR No 4: Linaclotide. Constella® in the symptomatic management of irritable bowel syndrome with constipation - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 4: Linaclotide. Constella® in the symptomatic management of irritable bowel syndrome with constipation DAR No 4: Linaclotide. Constella (...) ® in the symptomatic management of irritable bowel syndrome with constipation Content tools Share it The indication was granted...so what? Although authorized for irritable bowel syndrome with constipation it offers only symptomatic relief. In the best of cases, one in five patients can benefit from treatment. On the other hand, one in five patients can suffer from diarrhea as a secondary effect which can last for more than 28 days in half the cases. There are no available studies evaluating

2015 Drug and Therapeutics Bulletin of Navarre (Spain)

108. Sacral nerve stimulation for faecal incontinence and constipation in adults. Full Text available with Trip Pro

Sacral nerve stimulation for faecal incontinence and constipation in adults. Faecal incontinence (FI) and constipation are both socially-embarrassing and physically-disabling conditions that impair quality of life. For both, surgery may be required in a minority of people when more conservative measures fail. However, the invasiveness and irreversible nature of direct surgery on bowel and sphincter muscles, poor long-term outcomes and well-established compIications makes such procedures (...) unappealing for these benign conditions. A less-invasive surgical option to treat faecal incontinence and constipation is direct, low-voltage stimulation of the sacral nerve roots, termed sacral nerve stimulation (SNS). SNS has become the first line surgical treatment for FI in people failing conservative therapies. Its value in the treatment of constipation is less clear.To assess the effects of sacral nerve stimulation using implanted electrodes for the treatment of faecal incontinence and constipation

2015 Cochrane

109. Constipation Associated with a Lipoma. (Abstract)

Constipation Associated with a Lipoma. 26267625 2015 08 20 2016 11 25 1533-4406 373 7 2015 Aug 13 The New England journal of medicine N. Engl. J. Med. IMAGES IN CLINICAL MEDICINE. Constipation Associated with a Lipoma. 656 10.1056/NEJMicm1413283 Hardy C Lamar CL Naval Medical Center Portsmouth, Portsmouth, VA curtis.hardy@me.com. Goliath Gilbert G eng Case Reports Journal Article United States N Engl J Med 0255562 0028-4793 AIM IM Adolescent Constipation etiology Female Humans Intestinal

2015 NEJM

110. Naloxegol for treating opioid-induced constipation

Naloxegol for treating opioid-induced constipation Nalo Nalox xegol for treating opioid-induced egol for treating opioid-induced constipation constipation T echnology appraisal guidance Published: 22 July 2015 nice.org.uk/guidance/ta345 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful (...) a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Naloxegol for treating opioid-induced constipation (TA345) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 43Contents Contents 1 Guidance 4 2 The technology 5 3 The company's submission 6 Clinical effectiveness 6 Evidence Review

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

111. Polyethylene Glycol for the Treatment of Constipation in Patients in Acute and Long-Term Care: Cost-Effectiveness and Guidelines

Polyethylene Glycol for the Treatment of Constipation in Patients in Acute and Long-Term Care: Cost-Effectiveness and Guidelines Polyethylene Glycol for the Treatment of Constipation in Patients in Acute and Long-Term Care: Cost-Effectiveness and Guidelines | CADTH.ca Find the information you need Polyethylene Glycol for the Treatment of Constipation in Patients in Acute and Long-Term Care: Cost-Effectiveness and Guidelines Polyethylene Glycol for the Treatment of Constipation in Patients (...) in Acute and Long-Term Care: Cost-Effectiveness and Guidelines Published on: July 14, 2015 Project Number: RA0785-000 Product Line: Report Type: Reference List Result type: Report Question What is the cost-effectiveness of polyethylene glycol for the treatment of constipation in adults in acute or long-term care? What is the cost-effectiveness of polyethylene glycol for the treatment of constipation in children in acute or long-term care? What are the evidence-based guidelines regarding the use

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

112. Peristeen Anal Irrigation System for the Management of Incontinence and Constipation in Patients with VACTERL Association: Clinical Effectiveness and Cost-Effectiveness

Peristeen Anal Irrigation System for the Management of Incontinence and Constipation in Patients with VACTERL Association: Clinical Effectiveness and Cost-Effectiveness Peristeen Anal Irrigation System for the Management of Incontinence and Constipation in Patients with VACTERL Association: Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Peristeen Anal Irrigation System for the Management of Incontinence and Constipation in Patients with VACTERL (...) Association: Clinical Effectiveness and Cost-Effectiveness Peristeen Anal Irrigation System for the Management of Incontinence and Constipation in Patients with VACTERL Association: Clinical Effectiveness and Cost-Effectiveness Published on: July 7, 2015 Project Number: RA0779-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of the Peristeen anal irrigation system for the management of incontinence

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

113. Peristeen Anal Irrigation System for the Management of Incontinence and Constipation in Patients with VACTERL Association

Peristeen Anal Irrigation System for the Management of Incontinence and Constipation in Patients with VACTERL Association Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within (...) Irrigation System for the Management of Incontinence and Constipation in Patients with VACTERL Association: Clinical Effectiveness and Cost-Effectiveness DATE: 07 July 2015 RESEARCH QUESTIONS 1. What is the clinical effectiveness of the Peristeen anal irrigation system for the management of incontinence and constipation in patients with VACTERL association? 2. What is the cost-effectiveness of the Peristeen anal irrigation system for the management of incontinence and constipation in patients

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

114. The Diagnostic Value of a Digital Rectal Examination Compared With High-Resolution Anorectal Manometry in Patients With Chronic Constipation and Fecal Incontinence (Abstract)

The Diagnostic Value of a Digital Rectal Examination Compared With High-Resolution Anorectal Manometry in Patients With Chronic Constipation and Fecal Incontinence Digital rectal examination (DRE) is a simple clinical method to diagnose anorectal disorders. High-resolution antorectal manometry (HRAM) based on a spatiotemporal plot is expected to promote improved diagnostic accuracy. However, there are no reports comparing the effectiveness of DRE and HRAM. The aim of our study was therefore (...) to evaluate the diagnostic value of DRE compared with HRAM.A total of 309 consecutive patients with chronic constipation (n=268) or fecal incontinence (n=41) who underwent a standardized DRE, HRAM, and balloon expulsion test were enrolled in this study. The diagnostic yield of DRE compared with HRAM was determined, and agreement between DRE and HRAM data was evaluated.Of the constipated patients, 207 (77.2%) were diagnosed with dyssynergia using HRAM. The sensitivity, specificity, and positive predictive

2015 EvidenceUpdates

115. Laxatives for the management of constipation in people receiving palliative care. Full Text available with Trip Pro

Laxatives for the management of constipation in people receiving palliative care. This article describes the second update of a Cochrane review on the effectiveness of laxatives for the management of constipation in people receiving palliative care. Previous versions were published in 2006 and 2010 where we also evaluated trials of methylnaltrexone; these trials have been removed as they are included in another review in press. In these earlier versions, we drew no conclusions on individual (...) effectiveness of different laxatives because of the limited number of evaluations. This is despite constipation being common in palliative care, generating considerable suffering due to the unpleasant physical symptoms and the availability of a wide range of laxatives with known differences in effect in other populations.To determine the effectiveness and differential efficacy of laxatives used to manage constipation in people receiving palliative care.We searched the Cochrane Central Register of Controlled

2015 Cochrane

116. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Prucalopride in Men With Chronic Constipation Full Text available with Trip Pro

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Prucalopride in Men With Chronic Constipation Prucalopride is effective at alleviating symptoms of chronic constipation in women. The aim of this study was to assess the efficacy of 12 weeks of prucalopride treatment compared with placebo in men with chronic constipation.This was a multicenter, stratified, randomized, parallel-group, double-blind, placebo-controlled, phase 3 study (...) (ClinicalTrials.gov identifier: NCT01147926). The primary end point was the proportion of patients with a mean of three or more spontaneous complete bowel movements (SCBMs) per week across the treatment period. Efficacy end points were assessed using daily electronic diaries, global assessment of the severity of constipation and efficacy of treatment, and Patient Assessment of Constipation-Symptoms (PAC-SYM) and Patient Assessment of Constipation-Quality of Life (PAC-QOL) questionnaires.In total, 374 patients

2015 EvidenceUpdates Controlled trial quality: predicted high

117. Constipation. (Abstract)

Constipation. This issue provides a clinical overview of constipation, focusing on prevention, diagnosis, treatment, and patient information. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including ACP Smart Medicine and MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic from these primary sources in collaboration with the ACP's Medical

2015 Annals of Internal Medicine

118. Enemas for the Treatment of Constipation in the Emergency Department

Enemas for the Treatment of Constipation in the Emergency Department Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered (...) study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Enemas for the Treatment of Constipation

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

119. Colonoscopy in Patients with Constipation

Colonoscopy in Patients with Constipation Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types (...) , posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Colonoscopy in Patients with Constipation: Clinical Effectiveness and Guidelines DATE

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

120. Pharmacological treatment for antipsychotic-related constipation [Cochrane Protocol]

Pharmacological treatment for antipsychotic-related constipation [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2015 PROSPERO